NASDAQ: LTRNLantern Pharma Inc Stock
$5.72+0.38 (+7.12%)
Updated Apr 22, 2024
LTRN Price
$5.72
Fair Value Price
$2.00
Market Cap
$61.44M
52 Week Low
$2.38
52 Week High
$11.99
P/E
-3.89x
P/B
1.5x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$15.96M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.07
Operating Cash Flow
-$14M
Beta
0.97
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
LTRN Overview
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LTRN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LTRN ($5.72) is overvalued by 185.76% relative to our estimate of its Fair Value price of $2.00 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LTRN ($5.72) is not significantly undervalued (185.76%) relative to our estimate of its Fair Value price of $2.00 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LTRN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LTRN due diligence checks available for Premium users.
Be the first to know about important LTRN news, forecast changes, insider trades & much more!
LTRN News
Valuation
LTRN fair value
Fair Value of LTRN stock based on Discounted Cash Flow (DCF)
Price
$5.72
Fair Value
$2.00
Overvalued by
185.76%
LTRN ($5.72) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LTRN ($5.72) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LTRN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LTRN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.89x
Industry
16.21x
Market
41x
LTRN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.5x
Industry
5.82x
LTRN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LTRN's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.2M
Profit Margin
0%
LTRN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$43.6M
Liabilities
$2.7M
Debt to equity
0.07
LTRN's short-term assets ($43.34M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LTRN's short-term assets ($43.34M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LTRN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LTRN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.4M
Investing
$256.2k
Financing
-$500.0k
LTRN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LTRN vs Biotech Stocks
Lantern Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.